IN THE CLAIMS

The listing of the claims which follows replaces any and all prior versions and/or listings of the claims in the application.

1. (currently amended) A compound of Formula I, or an individual enantiomer or diastereomer thereof, or a pharmaceutically acceptable salt thereof:



(I)

wherein:

Z is N-R^9;

R^1 is -CH_2-R^J, and R^J is phenyl which is optionally substituted with from 1 to 4 substituents each of which is independently:

(1) -C_{1-4} alkyl,
(2) -O-C_{1-4} alkyl,
(3) -C_{1-4} haloalkyl,
(4) -O-C_{1-4} haloalkyl,
(5) halo,
(6) -CN,
(7) -N(R^A)R^B,
(8) -C(=O)N(R^A)R^B,
(9) -S(=O)R^A,
(10) -SO_2R^A,
(11) -N(R^A)SO_2R^B,
(12) -N(R^A)SO_2N(R^A)R^B,
(13) -N(R^A)C(=O)R^B, or
(14) -N(R^A)C(=O)-C(=O)N(R^A)R^B;

R^2 and R^4 are each independently:

(1) -H,

(2) -C_{1-6} alkyl, which is optionally substituted with -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -CN, -$N(R^A)R^B$, -$C(=O)N(R^A)R^B$, -$C(=O)R^A$, -CO_2R^A, -$S(O)_nR^A$, -$SO_2N(R^A)R^B$, -$N(R^A)C(=O)R^B$, -$N(R^A)CO_2R^B$, -$N(R^A)SO_2R^B$, -$N(R^A)SO_2N(R^A)R^B$, -$N(R^A)C(=O)N(R^A)R^B$, or -$OC(=O)N(R^A)R^B$,

(3) -C_{1-6} haloalkyl,

(4) CycA,

(5) AryA,

(6) HetC, or

(7) -C_{1-6} alkyl substituted with CycA, AryA, or HetC;

R^3 and R^5 are both H;

R^6 is:

(1) -H,

(2) -C_{1-6} alkyl,

(3) -C_{1-6} fluoroalkyl,

(4) CycA,

(5) AryA, or

(6) -C_{1-6} alkyl substituted with AryA;

R^7 is H or -C_{1-6} alkyl;

R^8 is:

(1) -H,

(2) -C_{1-6} alkyl,

(3) -CO_2R^A,

(4) -$C(=O)N(R^A)R^B$,

(5) -R^K,

(6) -$C(=O)$-R^K,

(7) -$C(=O)N(R^A)$-R^K, or

(8) -$C(=O)N(R^A)$-C_{1-6} alkylene-R^K;

or alternatively R^7 and R^8 together with the carbon atom to which they are both attached form a 3- to 7-membered saturated carbocyclic ring;

R^9 is:

(1) -H,
(2) -C_{1-6} alkyl,
(3) -C_{1-6} fluoroalkyl,
(4) CycA, or
(5) -C_{1-6} alkyl substituted with CycA, AryA, or HetC;

each n is independently an integer equal to zero, 1, or 2;

each R^A is independently H or C_{1-6} alkyl;

each R^B is independently H or C_{1-6} alkyl;

each R^K is independently CycA, AryA, or HetC;

each CycA is independently a C_{3-8} cycloalkyl, which is optionally substituted with from 1 to 4 substituents each of which is halogen, -OH, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, or -O-C_{1-6} haloalkyl;

each AryA is independently phenyl, which is optionally substituted with from 1 to 5 substituents each of which is independently -C_{1-6} alkyl, -C_{1-6} alkylene-OH, -C_{1-6} alkylene-O-C_{1-6} alkyl, -C_{1-6} alkylene-O-C_{1-6} haloalkyl, -C_{1-6} alkylene-$N(R^A)R^B$, -C_{1-6} alkylene-$C(=O)N(R^A)R^B$, -C_{1-6} alkylene-$C(=O)R^A$, -C_{1-6} alkylene-CO_2R^A, -C_{1-6} alkylene-$S(O)_nR^A$, -O-C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} haloalkyl, -OH, halo, -$N(R^A)R^B$, -$C(=O)N(R^A)R^B$, -$C(=O)R^A$, -CO_2R^A, -$S(O)_nR^A$, or -$SO_2N(R^A)R^B$; and

each HetC is independently a saturated or unsaturated heterocyclic ring which is:

(i) a saturated heterocyclic ring selected from the group consisting of piperidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, pyrrolidinyl, azetidinyl, imidazolidinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, hexahydropyrimidinyl, thiazinanyl, thiazepanyl, thiadiazepanyl, dithiazepanyl, azepanyl, diazepanyl, thiadiazinanyl, tetrahydropyranyl, tetrahydrothiopyranyl, and dioxanyl,

(ii) a mono-unsaturated heterocyclic ring selected from ~~and~~ mono-unsaturated counterparts of the saturated rings in (i), ~~thereof,~~ or

(iii) an aromatic heterocyclic ring selected from the group consisting of pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, oxatriazolyl, thiazolyl, isothiazolyl, and thiadiazolyl,

wherein the heterocyclic ring is optionally substituted with from 1 to 4 substituents each of which is halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, OH, or oxo.

2. (canceled)

3. (canceled)

4. (canceled)

5. (canceled)

6. (previously presented) The compound according to claim 1, or an individual enantiomer or diastereomer thereof, or a pharmaceutically acceptable salt thereof, wherein R^6 is H.

7. (canceled)

8. (canceled)

9. (previously presented) A compound according to claim 1, which is a compound of Formula IIa, or an individual enantiomer or diastereomer thereof, or a pharmaceutically acceptable salt thereof:



(IIa)

wherein:

X^1 and X^2 are each independently -H, -C_{1-4} alkyl, -O-C_{1-4} alkyl, -C_{1-4} haloalkyl, -O-C_{1-4} haloalkyl, halo, -CN, -N(R^A)R^B, -C(=O)N(R^A)R^B, or -S(O)$_n$$R^A$;

R^2 and R^4 are each independently -H, -C_{1-4} alkyl, -C_{1-4} fluoroalkyl, C_{3-6} cycloalkyl, phenyl, or benzyl;

R^6 is H, -C_{1-4} alkyl, CF_3, cyclopropyl, phenyl or benzyl;

R^7 is H or -C_{1-4} alkyl;

R^8 is -H, -C_{1-4} alkyl, -CO_2-C_{1-4} alkyl, -C(=O)NH(C_{1-4} alkyl), -C(=O)N(C_{1-4} alkyl)$_2$, C_{3-6} cycloalkyl, HetF, -C(=O)-HetE, or -C(=O)N(R^A)-(CH_2)$_{1-2}$-HetF; wherein

HetE is a saturated heterocyclic ring selected from the group consisting of piperidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, pyrrolidinyl, azetidinyl, imidazolidinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, hexahydropyrimidinyl, thiazinanyl, thiazepanyl, thiadiazepanyl, dithiazepanyl, azepanyl, diazepanyl, thiadiazinanyl, tetrahydropyranyl, tetrahydrothiopyranyl and dioxanyl, wherein the saturated heterocyclic is optionally substituted with from 1 to 3 substituents each of which is independently oxo or C_{1-4} alkyl; and with the proviso that the saturated heterocyclic is attached to the -C(=O)- via a ring N atom; and

HetF is a heteroaromatic ring selected from the group consisting of pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, oxatriazolyl, thiazolyl, isothiazolyl and thiadiazolyl, wherein the heteroaromatic ring is optionally substituted with 1 or 2 substituents each of which is independently a C_{1-4} alkyl;

or alternatively R^7 and R^8 together with the carbon atom to which they are both attached form a 3- to 6-membered saturated carbocyclic ring;

R^9 is -H, -C_{1-4} alkyl, -CH_2CF_3, -C_{3-6} cycloalkyl, -CH_2-C_{3-6} cycloalkyl, or -CH_2-phenyl;

each R^A is independently H or C_{1-4} alkyl; and

each R^B is independently H or C_{1-4} alkyl.

10. (previously presented) A compound according to claim 9, or an individual enantiomer or diastereomer thereof, or a pharmaceutically acceptable salt thereof, wherein:

X^1 and X^2 are each independently H, fluoro, chloro, methyl, trifluoromethyl, methoxy, CN, $-SO_2CH_3$, $-C(=O)NH(CH_3)$, or $-C(=O)N(CH_3)_2$;

R^2 and R^4 are both H;

R^6 is H, methyl, cyclopropyl, or phenyl;

R^7 is H or methyl;

R^8 is -H, $-C_{1-4}$ alkyl, $-CO_2-C_{1-4}$ alkyl, $-C(=O)NH(C_{1-4}$ alkyl), $-C(=O)N(C_{1-4}$ alkyl$)_2$, C_{3-6} cycloalkyl, HetF, -C(=O)-HetE, or $-C(=O)N(R^A)-(CH_2)_{1-2}$-HetF; wherein

HetE is selected from the group consisting of:





, and , wherein the asterisk * denotes the point of attachment to the -C(=O) moiety; and

HetF is selected from the group consisting of pyrrolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, pyridyl, pyrimidinyl, and pyrazinyl;

or alternatively R^7 and R^8 together with the carbon atom to which they are both attached form cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; and

R^9 is H, methyl, ethyl, n-propyl, isopropyl, $-CH_2CF_3$, cyclopropyl, or $-CH_2$-cyclopropyl.

11. (previously presented) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

2-(4-fluorobenzyl)-8-hydroxy-6-methyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

2-(4-fluorobenzyl)-8-hydroxy-5,5,6-trimethyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

(+)-2-(4-fluorobenzyl)-8-hydroxy-5,5,6-trimethyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

(-)-2-(4-fluorobenzyl)-8-hydroxy-5,5,6-trimethyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

2-(4-fluorobenzyl)-8-hydroxy-6-methyl-4a-phenyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

(+)-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-4a-phenyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

(-)-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-4a-phenyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

5-(tert-butyloxycarbonyl)-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione, and diastereomers and enantiomers thereof;

5-ethyl-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione, and diastereomers and enantiomers thereof;

6-(cyclopropylmethyl)-2-(4-fluorobenzyl)-8-hydroxy-5,5-dimethyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

5-(dimethylaminocarbonyl)-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione, and diastereomers and enantiomers thereof

2-(3-chloro-4-fluorobenzyl)-8-hydroxy-5,5,6-trimethy-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

(+)-2-(3-chloro-4-fluorobenzyl)-8-hydroxy-5,5,6-trimethy-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

(-)-2-(3-chloro-4-fluorobenzyl)-8-hydroxy-5,5,6-trimethy-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

6'-(4-fluorobenzyl)-4'-hydroxy-2'-methyl-6',7',8',8a'-tetrahydro-2' *H*-spiro[cyclopentane-1,1'-[2,6]naphthyridine]-3',5'-dione;

(+)-6'-(4-fluorobenzyl)-4'-hydroxy-2'-methyl-6',7',8',8a'-tetrahydro-2' *H*-spiro[cyclopentane-1,1'-[2,6]naphthyridine]-3',5'-dione;

(-)-6'-(4-fluorobenzyl)-4'-hydroxy-2'-methyl-6',7',8',8a'-tetrahydro-2' *H*-spiro[cyclopentane-1,1'-[2,6]naphthyridine]-3',5'-dione;

2-(3,4-difluorobenzyl)-8-hydroxy-5,5,6-trimethy-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

6'-(4-fluorobenzyl)-4'-hydroxy-2'-methyl-6',7',8',8a'-tetrahydro-2' *H*-spiro[cyclobutane-1,1'-[2,6]naphthyridine]-3',5'-dione;

5-[(2-methylpropyl)aminocarbonyl]-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione, and diastereomers and enantiomers thereof;

5-(tert-butylaminocarbonyl)-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione, and diastereomers and enantiomers thereof;

5-[(2-pyridylmethyl)aminocarbonyl]-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione, and diastereomers and enantiomers thereof

5-(pyrimidin-2-yl)-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione, and diastereomers and enantiomers thereof;

2-(3-chloro-4-fluorobenzyl)-8-hydroxy-6-cyclopropyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

(+)-2-(3-chloro-4-fluorobenzyl)-8-hydroxy-6-cyclopropyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione; and

(-)-2-(3-chloro-4-fluorobenzyl)-8-hydroxy-6-cyclopropyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione.

12. (previously presented) A pharmaceutical composition comprising an effective amount of a compound according to claim 1, or an individual enantiomer or diastereomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

13. (canceled)

14. (withdrawn) A method for treating infection by HIV or for treating or delaying the onset of AIDS in a subject in need thereof which comprises administering to the subject an effective amount of the compound according to claim 1, or an individual enantiomer or diastereomer thereof, or a pharmaceutically acceptable salt thereof.

15. (canceled)

16. (canceled)

17. (canceled)

18. (canceled)

19. (previously presented) A pharmaceutical combination which is (i) a compound according to claim 1, or an individual enantiomer or diastereomer thereof, or a pharmaceutically acceptable salt thereof, and (ii) an HIV infection/AIDS antiviral agent selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors and nucleoside HIV reverse transcriptase inhibitors; wherein the compound of (i) or its pharmaceutically acceptable salt and the HIV infection/AIDS antiviral agent of (ii) are each employed in an amount that renders the combination effective for inhibiting HIV integrase, for treating infection by HIV, or for treating or delaying the onset of AIDS.